Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02441283 · ClinicalTrials.gov registry record · Phase 2
A Study to Assess Resistance and Durability of Response to ABT-493 and/or ABT-530
A Phase 2 study, sponsored by AbbVie.
- Completed
- Registry status
- Phase 2
- Development phase
- 384
- Enrollment target
NCT02441283: Completed Phase 2 study, sponsored by AbbVie.
NCT02441283 is a Phase 2 study that has completed, run by AbbVie. The registered enrollment target is 384 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (189% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02441283, a Phase 2 study, has completed, sponsored by AbbVie.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 384 participants
- Enrollment target
Study Summary
This was a long-term follow-up study to evaluate the durability of sustained virologic response (SVR), persistence of direct-acting antiviral agent (DAA) resistance, and clinical outcomes for participants who received glecaprevir (ABT-493) and/or pibrentasvir (ABT-530) in prior AbbVie Phase 2 or 3 clinical studies for the treatment of chronic hepatitis C virus (HCV) infection.
Primary Outcome
Maintaining a sustained virologic response (SVR) is defined as having Hepatitis C virus ribonucleic acid (HCV RNA) value consistently below the lower limit of quantification (\< LLOQ) from the end of treatment in the previous study throughout Study M13-576 (this study).
Interventions
- DRUG ABT-493
- DRUG ABT-530
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 384 participants |
| Start Date | 2015-06-22 |
| Est. Completion | 2019-10-15 |
| Phase | Phase 2 |
What the finished NCT02441283 record still lists
NCT02441283 is an interventional study that assigns participants to a tested intervention. The registered 384 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (189% higher).
The record links to 0 conditions, and to 2 interventions - of which ABT-493 is the first listed.
NCT02441283 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02441283 about?
NCT02441283 is a clinical study titled "A Study to Assess Resistance and Durability of Response to ABT-493 and/or ABT-530". This was a long-term follow-up study to evaluate the durability of sustained virologic response (SVR), persistence of direct-acting antiviral agent (DAA) resistance, and clinical outcomes for participants who received glecaprevir (ABT-493) and/or pibrentasvir (ABT-530) in prior AbbVie Phase 2 or 3 c...
What is the current status of trial NCT02441283?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 384 participants. The study started on 2015-06-22. Estimated completion is 2019-10-15.
What interventions are being tested in trial NCT02441283?
The interventions under investigation include: ABT-493 (DRUG), ABT-530 (DRUG).
Who is sponsoring clinical trial NCT02441283?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02441283's enrollment target sits among peer trials
384 111th of 2000 higher than 1,890 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06277661 · 384 participants · NA
The Mom and Infant Outcomes (MOMI) Study
- NCT06372964 · 384 participants · Phase 3
Multicenter Study of Lumateperone for the Treatment of Bipolar Depression in Pediatric Patients
- NCT06501040 · 384 participants · NA
Increasing Knowledge and Interest in Cancer Clinical Trials
- NCT06566703 · 384 participants · NA
Testing ANSOS for Efficacy in Multi-Tribal Urban Communities
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI